April 29, 2014—There is new, more definitive evidence implicating camels in the ongoing outbreak of Middle East Respiratory Syndrome, or MERS. Scientists at the Center for Infection and Immunity at Columbia University’s Mailman School of Public Health, King Saud University, and EcoHealth Alliance extracted a complete, live, infectious sample of MERS coronavirus (MERS-CoV) from two camels in Saudi Arabia. The sample matched MERS-CoV found in humans, indicating that the virus in camels is capable of infecting humans and that camels are a likely source of the outbreak.
Results appear online in the journal mBio.
The researchers examined nasal samples collected during a countrywide survey of dromedary camels and selected samples from two animals with the highest viral load. They cultured and obtained complete genomic sequence from both animals as well as virus in nasal samples from several other camels.
The mathematical means of all genetic sequences (the consensus genomic sequences) were consistent with viruses found in human cases; however, samples from camels contained more than one virus genotype. Over a period of 48 hours of culture in primate cells, the genomic variation of viruses narrowed, mirroring the lower sequence diversity reported in MERS-CoV found in humans.
“The finding of infectious virus strengthens the argument that dromedary camels are reservoirs for MERS-CoV,” says first author Thomas Briese, PhD, associate director of the Center for Infection and Immunity and associate professor of Epidemiology at the Mailman School. “The narrow range of MERS viruses in humans and a very broad range in camels may explain in part why human disease is uncommon: because only a few genotypes are capable of cross species transmission,” adds Dr. Briese.
“Given these new data, we are now investigating potential routes for human infection through exposure to camel milk or meat products,” says co-author Abdulaziz N. Alagaili, PhD, director of the Mammals Research Chair at King Saud University. “This report builds on work published earlier this year when our team found that three-quarters of camels in Saudi Arabia carry MERS virus.”
To date, at least 300 people have been infected with the virus that causes MERS and approximately 100 have died since the first documented case in Saudi Arabia in September 2012. Of these, more than 60—about one-fourth of the global total since MERS was identified—have been reported in the past month. Most cases have been in Saudi Arabia, with lower numbers in Jordan, Qatar, Tunisia, and the United Arab Emirates. France, Germany, Italy, and the United Kingdom, and more recently Malaysia and the Philippines, have also reported cases related to travel to the Middle East. While human-to-human transmission has occurred, the source of the disease in most cases has remained a mystery.
“Although there is no evidence that MERS-CoV is becoming more transmissible, the recent increase in reported cases is a cause for concern,” says senior author W. Ian Lipkin, MD, director of the Center for Infection and Immunity and the John Snow Professor of Epidemiology at the Mailman School. “It is essential that investigators commit to data and sample sharing so that this potential threat to global health is addressed by the entire biomedical research community.”
Additional co-authors include Nischay Mishra and Komal Jain at CII; Iyad S. Zalmout and Osama B. Mohammed at KSU Mammals Research Chair; Omar J. Jabado at the Icahn Medical Institute; and William B. Karesh and Peter Daszak at EcoHealth Alliance.
The KSU Mammals Research Chair is supported by the Deanship of Scientific Research, King Saud University. Work in the Center for Infection and Immunity and EcoHealth Alliance is supported by awards from the National Institutes of Health (AI057158) and the United States Agency for International Development’s Emerging Pandemic Threat Program, PREDICT project, under terms of Cooperative Agreement Number GHN-A-OO-09-00010-00.
About Columbia University’s Mailman School of Public Health
Founded in 1922, Columbia University’s Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master’s and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP (formerly the International Center for AIDS Care and Treatment Programs) and the Center for Infection and Immunity. For more information, please visit www.mailman.columbia.edu.